BioTech
-
Readout Newsletter: BioNTech, Roche, Prometheus news
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your…
Read More » -
Surgeons perform first xenotransplant using CRISPR’d pig kidney
In a new test of xenotransplantation, a medical team at Massachusetts General Hospital announced Thursday that, for the first time,…
Read More » -
Feng Zhang suggests Editas didn’t move quickly enough to find product targets
When the first biotech companies emerged to capitalize on the revolutionary genome-editing technology CRISPR, Editas Medicine seemed like the pacesetter.…
Read More » -
CRISPR technology availability, affordability needs to be expanded
CRISPR is no longer a promising but unproven technology — it is a reality. But for this powerful gene-editing tool…
Read More » -
Yancopoulos of Regeneron works to expand Dupixent success
George Yancopoulos is in touch with his teenage self. After 35 years as head scientist at Regeneron Pharmaceuticals, Yancopoulos has…
Read More » -
Pfizer, Moderna say biotech, pharma drug development is a sprint
Drug development is more of a sprint than a marathon these days, thanks to more and better ways to target…
Read More » -
Readout Newsletter: Illumina, CRISPR, Regeneron
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your…
Read More » -
Biotech investment managers search for lucrative opportunities
Following a blockbuster year of dealmaking and a recent uptick in biotech stocks, top investors see more good news on…
Read More » -
FDA authorizes new drug to protect vulnerable from Covid-19
The Food and Drug Administration on Friday authorized a new antibody to protect immunocompromised individuals against Covid-19. The drug, known…
Read More » -
Covid vaccine financial winners and losers, from Pfizer to Novavax
It’s been four years since Covid-19 emerged, igniting a pandemic that killed millions of people and brought the world to…
Read More »